TY - JOUR
T1 - Challenges in IBD Research 2024
T2 - Novel Technologies
AU - Prasad, Shalini
AU - Cross, Raymond K.
AU - Monroe, Mary Beth
AU - Dolinger, Michael T.
AU - Motte, Rachel
AU - Hong, Sungmo
AU - Stidham, Ryan W.
AU - Kumar, Narendra
AU - Levine, Deborah
AU - Larijani, Anthony
AU - Simone, Ashley
AU - Chachu, Karen A.
AU - Wyborski, Russell
AU - Heller, Caren A.
AU - Moss, Alan C.
AU - Schwerbrock, Nicole M.J.
AU - Selaru, Florin M.
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Oxford University Press on behalf of Crohn's & Colitis Foundation. All rights reserved. For commercial re-use, please contact [email protected] for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site-for further information please contact [email protected].
PY - 2024/5/1
Y1 - 2024/5/1
N2 - Novel technology is one of the five focus areas of the Challenges in Inflammatory Bowel Disease (IBD) Research 2024 document. Building off the Challenges in IBD Research 2019 document, the Foundation aims to provide a comprehensive overview of current gaps in IBD research and deliver actionable approaches to address them with a focus on how these gaps can lead to advancements in interception, remission, and restoration for these diseases. The document is the result of a multidisciplinary collaboration from scientists, clinicians, patients, and funders and represents a valuable resource for patient-centric research prioritization. Specifically, the Novel Technologies section focuses on addressing key research gaps to enable interception and improve remission rates in IBD. This includes testing predictions of disease onset and progression, developing novel technologies tailored to specific phenotypes, and facilitating collaborative translation of science into diagnostics, devices, and therapeutics. Proposed priority actions outlined in the document include real-Time measurement of biological changes preceding disease onset, more effective quantification of fibrosis, exploration of technologies for local treatment of fistulas, and the development of drug delivery platforms for precise, location-restricted therapies. Additionally, there is a strong emphasis on fostering collaboration between various stakeholders to accelerate progress in IBD research and treatment. Addressing these research gaps necessitates the exploration and implementation of bio-engineered novel technologies spanning a spectrum from materials to systems. By harnessing innovative ideas and technologies, there's a collective effort to enhance patient care and outcomes for individuals affected by IBD.
AB - Novel technology is one of the five focus areas of the Challenges in Inflammatory Bowel Disease (IBD) Research 2024 document. Building off the Challenges in IBD Research 2019 document, the Foundation aims to provide a comprehensive overview of current gaps in IBD research and deliver actionable approaches to address them with a focus on how these gaps can lead to advancements in interception, remission, and restoration for these diseases. The document is the result of a multidisciplinary collaboration from scientists, clinicians, patients, and funders and represents a valuable resource for patient-centric research prioritization. Specifically, the Novel Technologies section focuses on addressing key research gaps to enable interception and improve remission rates in IBD. This includes testing predictions of disease onset and progression, developing novel technologies tailored to specific phenotypes, and facilitating collaborative translation of science into diagnostics, devices, and therapeutics. Proposed priority actions outlined in the document include real-Time measurement of biological changes preceding disease onset, more effective quantification of fibrosis, exploration of technologies for local treatment of fistulas, and the development of drug delivery platforms for precise, location-restricted therapies. Additionally, there is a strong emphasis on fostering collaboration between various stakeholders to accelerate progress in IBD research and treatment. Addressing these research gaps necessitates the exploration and implementation of bio-engineered novel technologies spanning a spectrum from materials to systems. By harnessing innovative ideas and technologies, there's a collective effort to enhance patient care and outcomes for individuals affected by IBD.
KW - Crohn's disease
KW - bioengineering
KW - fibrosis
KW - real-Time measurement
KW - targeting inflammation
KW - ulcerative colitis
UR - http://www.scopus.com/inward/record.url?scp=85194025893&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85194025893&partnerID=8YFLogxK
U2 - 10.1093/ibd/izae082
DO - 10.1093/ibd/izae082
M3 - Article
C2 - 38778625
AN - SCOPUS:85194025893
SN - 1078-0998
VL - 30
SP - S30-S38
JO - Inflammatory bowel diseases
JF - Inflammatory bowel diseases
IS - Supplement_2
ER -